Seventy-eight-year-old Joe Walsh, of Quincy, is in a unique position.
He is the first patient to have permission from the U.S. Food and Drug Administration to try a nasal spray for moderate Alzheimer’s disease under the federal agency’s expanded access, or “compassionate use,” program.
